Key contacts

Will Corkill

Will Corkill
Director

Simon Wilson

Simon Wilson
Director

Regional office - Australia
Level 25
Aurora Place
88 Phillip Street
Sydney
NSW 2000
Australia
Tel: +61 (0)2 9258 1161

Regional office - New Zealand
Level 15
171 Featherston Street
Wellington 6011
New Zealand
Tel: +64 (0)4 8948555

swilson@edisongroup.com
wcorkill@edisongroup.com

listed companies

Range Resources Nkwe Platinum
MEC Resources Coal of Africa
Syndicated Metals Gold One
Bionomics Allied Gold Mining
Phylogica ADX Energy
Alkane Resources Bellzone Mining
Sumatra Copper & Gold Continental Coal
Gunson Resources RedFlow
Lochard Energy Circadian Technologies
Universal Coal Biotron
See more

Companies with HQs in asia-pacific

Seeing Machines Forterra Trust
Greka Drilling Bezant Resources
Green Dragon Gas Baobab Resources
Endace Wynnstay Group
PXP Vietnam Fund Chatham Rock Phosphate
Tenon MMG
SeaDragon Contact Energy
Cue Energy New Zealand Oil & Gas
Rubicon Sky Network Television
Sealegs Corporation Kreuz Holdings
See more

Latest research

Alkane Resources

TGO in line with guidance, DZP shovel ready

Update | Mining | 26/07/2016

The TGO gold mine continues to perform well, helped in no small part by a resurgent gold price during H216, and despite unseasonably high rainfall persisting through Q416. Stronger cash flows resulted and we expect the TGO to continue at similar operating levels (to FY16) through FY17. The DZP continues to advance, albeit with a number of concurrent project elements requiring completion before financing can be finalised.

Leaf Resources

Claeris JV to accelerate Glycell commercialisation

Update | Alternative Energy | 20/07/2016

Leaf Resources (LER) has entered into agreements with US-based Claeris, LLC to establish a JV entity, Leaf Development, to develop up to five renewable chemical projects using LER’s proprietary Glycell process. Claeris provides connections to a global network of organisations and professionals involved in the development of renewable chemical projects.

Sealegs Corporation

Refocused and delivering

Update | Engineering | 11/07/2016

Sealegs has demonstrated that its refocus on fitting its technology to original equipment manufacturer (OEM) hulls is working. The company reported a significant turnaround in operating performance in FY16, with normalised NPAT of NZ$589,000, its first profit in three years and well ahead of our forecast for NPAT of NZ$115,312. On a 12-month forward P/E of 157x, Sealegs is trading at a 16% discount to its peers.

Mesoblast

Teva returns rights to cardiovascular programme

Outlook | Pharmaceutical & Healthcare | 08/07/2016

Teva has relinquished all rights to cardiovascular applications of Mesoblast’s mesenchymal precursor cell (MPC) technology, as it focuses on its core CNS and respiratory interests. Mesoblast will seek a new partner with a cardiovascular focus at the appropriate time. It has entered an A$120m (~US$90m) equity finance facility with Kentgrove Capital to fund the ongoing Phase III CHF trial and a 600-patient confirmatory trial (estimated cost ~US$90m), and has brought forward the interim futility…

Pacific Edge

On the road to full US commercialisation

Outlook | Pharmaceutical & Healthcare | 26/06/2016

Pacific Edge has made solid progress in recent months toward the start of broad commercialisation of its bladder cancer diagnostics tests in the US, with a third test becoming available there in mid-2016. In February, the Veterans Administration (VA) handed down a positive decision on its Cxbladder testing technology just as large-scale User Programmes in the US near completion. The Kaiser Permanente (KP) pilot is expected to be completed by the end of 2016 and could result in significant sales traction.

About

Edison‘s Sydney and Wellington offices opened in 2011 to provide research services to companies listed on Asia-Pacific stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports See more sector reports See more sector reports